Ariad Pharmaceuticals CEO Harvey Berger has a message for investors: "The company ($ARIA) is not for sale." It is, though, in partnership talks regarding its leukemia drug ponatinib. Ariad wants an Asian deal for the drug, which it plans to market itself in the U.S., provided it can win an approval. The CEO adds that he expects to launch the drug in late 2012 or early '13. Story